Drug Patents owned by Genus Lifesciences
1. Drug name - GOPRELTO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10933060 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10973811 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10987347 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10894012 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10857095 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10231961 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US11040032 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10016407 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US9867815 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10413505 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10420760 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
| US10149843 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(14 years from now) | |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; method of administering a local anesthetic to the mucous membranes in patients with renal impairment; method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic to the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Method of administering a local anesthetic to the mucous membranes; method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes
Dosage: SOLUTION;NASAL
| Strength | Dosage | Availability |
|---|---|---|
| 4% | SOLUTION;NASAL | Prescription |
2. Drug name - LEVOLET
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10231931 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(15 years from now) | |
| US10406108 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(15 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET;ORAL | Prescription |
3. Drug name - YOSPRALA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6926907 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(4 months from now) | |
| US8206741 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(4 months from now) | |
| US9987231 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Jan, 2033
(10 years from now) | |
| US9539214 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Mar, 2033
(10 years from now) | |
Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient
Treatment: Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers; For secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers
Dosage: TABLET, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 81MG;40MG | TABLET, DELAYED RELEASE;ORAL | Discontinued |
| 325MG;40MG | TABLET, DELAYED RELEASE;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.